Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has thrown a challenge to the scientific community. Several interventions to stop or limit the spread of infection have failed, and every time the virus emerges, it becomes more contagious and more deadly. Vaccinating a significant proport...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2022/6913772 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545836416892928 |
|---|---|
| author | Syed Mohammed Basheeruddin Asdaq Shahamah Jomah Syed Imam Rabbani Ali Musharraf Alamri Salman Khalaf Salem Alshammari Badr Sami Duwaidi Majed Sadun Alshammari Abdulhakeem S. Alamri Walaa F. Alsanie Majid Alhomrani Nagaraja Sreeharsha Mohd. Imran |
| author_facet | Syed Mohammed Basheeruddin Asdaq Shahamah Jomah Syed Imam Rabbani Ali Musharraf Alamri Salman Khalaf Salem Alshammari Badr Sami Duwaidi Majed Sadun Alshammari Abdulhakeem S. Alamri Walaa F. Alsanie Majid Alhomrani Nagaraja Sreeharsha Mohd. Imran |
| author_sort | Syed Mohammed Basheeruddin Asdaq |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has thrown a challenge to the scientific community. Several interventions to stop or limit the spread of infection have failed, and every time the virus emerges, it becomes more contagious and more deadly. Vaccinating a significant proportion of the population is one of the established methods to achieve herd immunity. More than 100 COVID-19 vaccines have been designed and tested against the virus. The development of a new vaccine takes years of testing, but due to the pandemic, healthcare authorities have given emergency use authorization for a few vaccines. Among them are BioNTech and Moderna vaccines (mRNA based); ChAdOx1, Gam-COVID-Vac, Janssen vaccines (vector-based); CoronaVac, COVAXIN (virus inactivated); and EpiVacCorona vaccine (viral peptide). Mixtures of vaccines are also being tested to evaluate their efficacy against mutant strains of SARS-CoV-2. All these vaccines in clinical trials have shown robust production of neutralizing antibodies sufficient to prevent infection. Some of the vaccinated people reported serious complications. However, no definitive relationship could be established between vaccination administration and the occurrence of these complications. None of the COVID-19 vaccines approved to date have been found to be effective against all of the SARS-CoV-2 variants. |
| format | Article |
| id | doaj-art-24347b74828e420690ac19be176a2004 |
| institution | Kabale University |
| issn | 1918-1493 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-24347b74828e420690ac19be176a20042025-02-03T07:24:28ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1918-14932022-01-01202210.1155/2022/6913772Insight into the Advances in Clinical Trials of SARS-CoV-2 VaccinesSyed Mohammed Basheeruddin Asdaq0Shahamah Jomah1Syed Imam Rabbani2Ali Musharraf Alamri3Salman Khalaf Salem Alshammari4Badr Sami Duwaidi5Majed Sadun Alshammari6Abdulhakeem S. Alamri7Walaa F. Alsanie8Majid Alhomrani9Nagaraja Sreeharsha10Mohd. Imran11Department of Pharmacy PracticePharmacy DepartmentDepartment of Pharmacology and ToxicologyKing Abdulaziz Medical CityKing Abdulaziz Medical CityKing Abdulaziz Medical CityKing Abdulaziz Medical CityDepartment of Clinical Laboratory SciencesDepartment of Clinical Laboratory SciencesDepartment of Clinical Laboratory SciencesDepartment of Pharmaceutical SciencesDepartment of Pharmaceutical ChemistrySevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has thrown a challenge to the scientific community. Several interventions to stop or limit the spread of infection have failed, and every time the virus emerges, it becomes more contagious and more deadly. Vaccinating a significant proportion of the population is one of the established methods to achieve herd immunity. More than 100 COVID-19 vaccines have been designed and tested against the virus. The development of a new vaccine takes years of testing, but due to the pandemic, healthcare authorities have given emergency use authorization for a few vaccines. Among them are BioNTech and Moderna vaccines (mRNA based); ChAdOx1, Gam-COVID-Vac, Janssen vaccines (vector-based); CoronaVac, COVAXIN (virus inactivated); and EpiVacCorona vaccine (viral peptide). Mixtures of vaccines are also being tested to evaluate their efficacy against mutant strains of SARS-CoV-2. All these vaccines in clinical trials have shown robust production of neutralizing antibodies sufficient to prevent infection. Some of the vaccinated people reported serious complications. However, no definitive relationship could be established between vaccination administration and the occurrence of these complications. None of the COVID-19 vaccines approved to date have been found to be effective against all of the SARS-CoV-2 variants.http://dx.doi.org/10.1155/2022/6913772 |
| spellingShingle | Syed Mohammed Basheeruddin Asdaq Shahamah Jomah Syed Imam Rabbani Ali Musharraf Alamri Salman Khalaf Salem Alshammari Badr Sami Duwaidi Majed Sadun Alshammari Abdulhakeem S. Alamri Walaa F. Alsanie Majid Alhomrani Nagaraja Sreeharsha Mohd. Imran Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
| title_full | Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
| title_fullStr | Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
| title_full_unstemmed | Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
| title_short | Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines |
| title_sort | insight into the advances in clinical trials of sars cov 2 vaccines |
| url | http://dx.doi.org/10.1155/2022/6913772 |
| work_keys_str_mv | AT syedmohammedbasheeruddinasdaq insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT shahamahjomah insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT syedimamrabbani insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT alimusharrafalamri insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT salmankhalafsalemalshammari insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT badrsamiduwaidi insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT majedsadunalshammari insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT abdulhakeemsalamri insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT walaafalsanie insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT majidalhomrani insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT nagarajasreeharsha insightintotheadvancesinclinicaltrialsofsarscov2vaccines AT mohdimran insightintotheadvancesinclinicaltrialsofsarscov2vaccines |